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Purpose. To evaluate the efficacy of Ahmed Glaucoma Valve (AGV) implantation in patients with refractory glaucoma in a tertiary
hospital in Brazil.Methods. Retrospective case series of patients who underwent AGV implantation. Primary outcome was to assess
the rate of failure, which was defined as intraocular pressure (IOP) in two consecutive visits greater than 18 or lower than 5 mmHg
(criterion 1) or IOP greater than 15 or lower than 5mmHg (criterion 2). The secondary outcome was to investigate risk factors
for failure. Results. 112 eyes from 108 patients underwent AGV implantation between 2000 and 2012. Mean follow-up time was
2.54 (±1.52) years. Kaplan-Meier survival analysis showed cumulative probabilities of success of 80.3%, 68.2%, and 47.3% at 1, 3,
and 5 years using 18mmHg as endpoint. When adopting 15mmHg as endpoint, cumulative success rates were 80.3%, 60.7%, and
27.3% at 1, 3, and 5 years, respectively. Multivariate analysis with generalized estimating equations revealed that African American
ancestry and early hypertensive phase were risk factors for failure (𝑃 = 0.001 and 𝑃 = 0.002, resp.). Conclusion. A success rate of
approximately 50%was obtained 5 years after the implantation of an AGV. African American ancestry and early hypertensive phase
were associated with increased risk of failure.
1. Introduction
Glaucoma drainage devices are typically reserved for refrac-
tory glaucomas, which are associated with high risk for
failure, such as neovascular or uveitic glaucoma or after
failed trabeculectomies [1, 2]. Although trabeculectomy still
remains as the first-line surgical treatment for glaucoma,
the use of drainage devices is becoming more common.
Previous comparative studies were not able to demonstrate
the superiority of trabeculectomy but reported fewer early
postoperative complications when performing a glaucoma
drainage device implantation [3, 4].
Ramulu et al. reported an increase from 2728 drainage
device surgeries in 1995 to 7744 in 2004 according to Medi-
care data in the United States [5]. However, cost-effectiveness
analysis and long-term follow-up are needed to evaluate if
glaucoma drainage device can be used as primary surgical
option. The Ahmed Glaucoma Valve (AGV) (New World
Medical, Cucamonga, CA) and the Baerveldt glaucoma
drainage implant (Abbott Medical Optics, Abbott Park, IL)
are the two most commonly used glaucoma drainage devices
[6, 7]. The AGV has a flow restrictor designed to reduce
postoperative hypotony.
The “Ahmed Baerveldt Comparison Study” showed
cumulative probabilities of failure of 31.3% and 44.7% after 3
and 5 years, respectively, following an AGV surgery [7, 8]. On
the other hand, the “Ahmed versus Baerveldt Study” showed
cumulative probability of failure of 51% after 3 years of AGV
implantation [6]. There is no previous report of long-term
follow-up of AGV surgeries in Brazil. The aim of the study is
to analyze the survival rates of AGV implantation in patients
with refractory glaucoma in a tertiary hospital in Brazil and
identify possible risk factors for failure.
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2. Methods
2.1. Patient Selection. This was a retrospective study, eval-
uating patients with refractory glaucoma who underwent
an AGV implantation at Hospital das Clinicas, University
of Campinas, Brazil. “Refractory glaucoma” was defined
as glaucomas associated with a poor surgical prognosis
after trabeculectomy, which remained uncontrolled despite
previous filtration surgery and/or laser treatment and/or
under maximum tolerated medical treatment. Only patients
with at least 1 year of follow-up were included in the study,
unless failure occurred before that period. All procedures
were performed between January 2000 and November 2012.
This study was approved by the Ethics Committee of the
University of Campinas and adhered to the tenets of the
Declaration of Helsinki. Medical records were retrospec-
tively reviewed for preoperative and postoperative follow-
up information, such as occurrence of complications. At
each visit during follow-up, subjects underwent a com-
prehensive ophthalmic examination, including Snellen best
corrected visual acuity, slit-lamp biomicroscopy, intraocular
pressure (IOP) measurement using Goldmann applanation
tonometry, gonioscopy, and dilated fundoscopy examination
using a 78-diopter lens. Flat anterior chambers were graded
according to the classification proposed by Spaeth [9].
2.2. Primary and Secondary OutcomeMeasures. The primary
outcome measure of this study was to establish the rates of
failure, which was defined by two consecutive visits with
IOP greater than 18mmHg or lower than 5mmHg (criterion
1) or IOP greater than 15mmHg or lower than 5mmHg
(criterion 2) after 3 months of surgery. Failure was also
defined as the need of an additional glaucoma surgery for IOP
control or loss of light perception during follow-up. Severe
complications such as tube or plate exposure in which the
implant had to be removed were also considered as failure.
The secondary outcome of the study was to identify possible
risk factors for failure following AGV surgery.
2.3. Surgical Technique and Postoperative Follow-Up. Surg-
eries were performed by experienced attending glaucoma
surgeons (JPV, RBC, and VPC) or by glaucoma fellows under
their direct surgical supervision.The AGVmodels used were
the S2 polypropylene (184mm2 surface area) and FP7 silicone
(184mm2 surface area). All surgeries were performed with
peribulbar anaesthesia. A fornix-based conjunctival flap was
fashioned preferably in the superotemporal quadrant. AGV
was primed by flushing balanced salt solution through the
tube to confirm patency. The anterior edge of the plate was
secured with 9-0 nylon sutures to the sclera at least 8mm
from the limbus. A 23-gauge needle was used 1mm posterior
to the limbus to create a track and access the anterior cham-
ber. A rectangular donor scleral patch graft (4 × 6mm) was
fashioned and sutured over the tube using 10-0 nylon sutures.
The conjunctiva was also secured with 10-0 nylon sutures. No
antimetabolites were used in the procedure. Follow-up visits
were scheduled 1 day, 3 days, 1 week, 2 weeks, and 1, 3, 6, 12,
and 18 months; after that, patients were followed within a 6-
month interval. All patients received a standard regimen of
topical antibiotic drops (moxifloxacin hydrochloride) q.i.d,
discontinued after 2 weeks. Topical corticosteroids drops
(prednisolone acetate ophthalmic suspension 1%) were used
initially 6 times daily and tapered gradually over 6 to 10
weeks depending on the degree of inflammation. Glaucoma
medicationswere prescribed according to IOPmeasurements
and the severity of the disease. An early hypertensive phase
(EHP) was defined as an IOP increase of more than 21mmHg
within the first 3 months after surgery and after a reduction
of IOP to less than 21mmHg had been achieved during the
first postoperative week [10, 11].
2.4. Statistical Analysis. Snellen visual acuity and the semi-
quantitative scale “counting fingers,” “hand motion,” and
“light perception” were converted to logarithm of the mini-
mum angle of resolution (logMAR) for analysis [12]. Cumu-
lative survival rates were calculated using Kaplan-Meier
survival analysis. We included variables previously listed as
risk factors according to [10, 13, 14]. Since both eyes of some
patients were evaluated, univariate and multivariate analyses
were performed with generalized estimating equations with
the exponentiation results presented in Odds Ratios. Statisti-
cal analysis and artwork were performed using Stata, version
13 (StataCorp LP, College Station, Texas, USA). The alpha
level (type I error) was set at 0.05.
3. Results
The present study included 112 eyes from 108 glaucoma
patients who underwent an AGV implant. Table 1 shows
clinical and demographic characteristics of the subjects.
Patients were followed for an average of 2.54 ± 1.52 years.
Mean age was 59.73 ± 17.65 years. Among the 112 eyes, 58
received the Ahmed S2 valve (51.79%), and 54 eyes (48.21%)
underwent Ahmed FP7 valve implantation. A total of 71 eyes
(63.39%) had filtering surgery prior to theAGV implantation.
The most common type of glaucoma was primary open
angle glaucoma (POAG) (50.89%), followed by neovascular
(20.54%), traumatic (6.09%), congenital (5.36%), and uveitic
glaucoma (4.46%). This distribution is similar to previous
studies such as Ahmed Baerveldt Comparison Study and
the Ahmed Versus Baerveldt Study [6, 8]. Baseline average
and postoperative logMAR visual acuity were 1.13 ± 0.68
and 1.23 ± 0.64, respectively (𝑃 = 0.021) (Table 2). Mean
IOP before surgery was 29.00 ± 9.72mmHg and 16.69 ±
7.08mmHg at the last follow-up (𝑃 < 0.001). Mean number
of medications decreased from 3.50 ± 0.67 prior to surgery to
2.44 ± 1.27 at the last follow-up (𝑃 < 0.001) (Table 2).
Kaplan-Meier analysis utilizing criterion 1 (5mmHg <
IOP < 18mmHg) showed cumulative survival rates of 80.3%,
68.2%, and 47.3%, after 1, 3, and 5 years, respectively. When
criterion 2 was employed (5mmHg < IOP < 15mmHg),
cumulative survival rates of 80.3%, 60.7%, and 27.3% were
observed after 1, 3, and 5 years, respectively. The most
common reason for failure was reintervention due to high
IOP levels (69.2%) (Table 3). Among the 39 failures, 2 patients
(5.1%) had severe complications and 6 patients (15.3%)
lost light perception during follow-up. We observed three
(1.6%) intraoperative complications (hyphema, lens touch,
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Table 1: Demographic and clinical characteristics of study patients.
Parameters Total subjects (𝑛 = 108)
Follow-up (years)
Mean ± SD 2.54 ± 1.52
Range 0.33 to 6.00
Age (years)
Mean ± SD 59.73 ± 17.65
Range 14 to 86
Gender, 𝑛 (%)
Male 58 (53.70%)
Female 50 (46.30%)
Race, 𝑛 (%)
Caucasian 84 (77.78%)
African American 21 (19.44%)
Others 2 (2.87%)
Comorbidity, 𝑛 (%)
Hypertension 27 (37.50%)
Diabetes 24 (33.33%)
Parameters Total eyes (𝑛 = 112)
Eye, 𝑛 (%)
Right 60 (53.57%)
Left 52 (46.43%)
Previous glaucoma surgery, 𝑛 (%)
Yes 71 (63.39%)
Type of implant, 𝑛 (%)
Ahmed S2 58 (51.79%)
Ahmed FP7 54 (48.21%)
Type of glaucoma, 𝑛 (%)
Primary open angle 57 (50.89%)
Neovascular 23 (20.54%)
Traumatic 7 (6.09%)
Congenital 6 (5.36%)
Uveitic 5 (4.46%)
Penetrating keratoplasty 5 (4.46%)
Primary angle closure 2 (1.79%)
Others 7 (6.09%)
SD: standard deviation; S2: polypropylene; FP7: silicone.
Table 2: Comparison between baseline and postoperative visual
acuity, intraocular pressure, and glaucoma medications.
Parameters Baseline Postoperative 𝑃 value
Visual acuity (logMAR)
Mean ± SD 1.13 ± 0.68 1.23 ± 0.64 0.021
IOP
Mean ± SD 29.00 ± 9.72 16.69 ± 7.08 <0.001
Glaucoma medications
Mean ± SD 3.50 ± 0.67 2.44 ± 1.27 <0.001
SD: standard deviation; IOP: intraocular pressure.
and malignant glaucoma) (Table 4). The most common early
complication was choroidal detachment (6 cases, 5.0%),
which occurred after a mean of 4.4 days after surgery,
Table 3: Reasons for treatment failure after AhmedGlaucomaValve
surgery.
Reason for failure 𝑁 (%)
18mmHg < IOP < 5mmHg and reintervention for
IOP control 27 (69.2%)
18mmHg < IOP < 5mmHg or 2 (5.12%)
Reintervention for IOP control 2 (5.12%)
Severe complications 2 (5.12%)
Loss of light perception 6 (15.3%)
IOP: intraocular pressure.
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Figure 1: Percentage of success after Ahmed Glaucoma Valve
implantation in Caucasian and African American patients, using
failure definition of intraocular pressure greater than 18mmHg
and less than 5mmHg. Univariate analysis showed that African
American ancestry was a risk factor for failure (𝑃 = 0.001).
followed by shallow anterior chamber grades 1 and 2 (5 cases,
4.2%), occurring after amean of 3 days after surgery (Table 4).
Themost common late complicationwas implant exposure (5
cases, 4.2%), after a mean of 10.2 months (Table 4).
Univariate analysis (based on criterion 1) showed that
African American (Figure 1) descent and EHP (Figure 2)
were risk factors for failure (𝑃 = 0.001; 𝑃 < 0.001, resp.)
(Table 5). Other covariates such as age, gender, previous
glaucoma filtering surgery, the type of the implant used, and
other types of glaucomawere not significantly associatedwith
failure. On the multivariate analysis (based on criterion 1),
African-American descent and EHP remained as risk factors
for failure (𝑃 = 0.001 and 𝑃 = 0.002, resp.). African
American patients had a risk of 5.51 (CI, confidence interval)
(CI: 2.32–19.06) and patients with EHP had a risk of 4.88 (CI:
1.74–11.60) for AGV failure (Table 5).
We also performed a separate analysis to study the effects
of EHP on the African American and Caucasian patients.
Univariate analysis (based on criterion 1) showed that, in
the African American group, EHP was not considered a risk
factor for failure (𝑃 = 0.605), whereas in theCaucasian group,
EHP had odds ratio of 7.36 (CI: 2.62–12.62; 𝑃 < 0.001).
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Table 4: Intraoperatory, early and late complications related to Ahmed Glaucoma Valve surgery.
Intraoperatory complications
Complication Number of cases Time
Hyphema 1 N/A
Lens touch 1 N/A
Malignant glaucoma 1 N/A
Early complications
Complication Number of cases Time in days (mean)
Choroidal detachment 6 4.2
Shallow anterior chamber grades 1 and 2 5 3.3
Shallow anterior chamber grade 3 4 5.75
Hypotony maculopathy 3 6.6
Hyphema 2 1
Corneal edema 2 1
Endophthalmitis 1 3
Tube-corneal touch 1 3
Tube exposure 1 7
Late complications
Complication Number of cases Time in months (mean)
Tube exposure 5 10.2
Corneal edema 4 2
Phthisis bulbi 2 3
Tube extrusion 2 16.5
Vitreous hemorrhage 2 18.5
Retinal detachment 2 4.5
Cystoid macular edema 1 3
Macular hole 1 6
Strabismus 1 6
Plate exposure 1 12
Hyphema 1 12
Uveitis 1 24
4. Discussion
The present study disclosed a cumulative success rate of
80.3% at 1 year, 68.2% at 3 years and 47.3% at 5 years using
18mmHg as endpoint. For a stricter endpoint (15mmHg),
cumulative success rates were 80.3%, 60.7% and 27.3% at 1, 3
and 5 years, respectively. In the current study, the cumulative
success rate was different from the results of the “Ahmed
Baerveldt Comparison Study” (cumulative probabilities of
success of 68.7% and 55.3% after 3 and 5 years, resp.), because
they defined failure as IOPmore than 21mmHg [8]. However,
our results were similar to the “Ahmed Versus Baerveldt
Study” (with cumulative probability of success of 49% after
3 years), which used the same of IOP levels (5 to 18mmHg)
as in our study [6]. Although not common in the literature,
adopting a stricter criterion (15mmHg) for the definition
of surgical success is important due to the fact that some
patients with advanced glaucoma need lower IOP levels to
avoid progression of the disease.
The secondary outcome of this study was to identify
possible risk factors for failure following AGV implantation.
According to the multivariate analysis, African American
descent was significantly associated with risk of failure. This
finding is in agreement with a previous study from Ishida and
Netland, where 86 eyes from 43 African Americans and 43
Caucasian patients were followed for an average of 2.5 years
after AGV implantation [14]. In their study, two different
definitions for success were adopted. The first was based on
IOP levels between 6 and 21mmHg with or without the use
of additional glaucoma medications. The second definition
required the same IOP levels and also a 20% IOP reduction
from baseline. Despite not finding statistically significant
differences regarding the number of complications andmean
IOPs during follow-up, the authors reported that African
American ancestry was a risk factor for surgical failure for
both definitions (𝑃 = 0.030 and 𝑃 = 0.006, resp.).
The pathophysiological basis underlying racial differ-
ences on AGV implant survival is unknown. Several studies
confirmed that African American ancestry is characterized
by high prevalence and rapid progression of glaucoma [15,
16]. Additionally, medical therapy seems to be less effective
in African Americans when compared to Caucasians [17].
Finally, there is evidence suggesting a higher failure rate for
trabeculectomy in African American patients [18].
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Table 5: Univariate and multivariate analysis to evaluate risk factors following Ahmed Glaucoma Valve surgery.
Risk factors Univariate Multivariate
Parameters OR 𝑃 value OR 95% CI 𝑃 value
Age (y)
≥60 years 0.98 0.087 0.78 0.28–2.12 0.631
<60 years
Gender
Male 1.3 0.504 1.21 0.46–3.21 0.693
Female
Race
White 5.27 0.001 5.51 2.32–19.06 0.001
African American
Previous glaucoma surgery
Yes 1.01 0.997 1.74 0.44–6.79 0.423
No
Type of glaucoma
Primary open angle 0.46 0.068 0.99 0.26–4.91 0.989
Neovascular glaucoma 1.43 0.444 3.18 0.59–16.80 0.229
Uveitic 7.56 0.075 6.86 0.90–11.10 0.060
Traumatic 1.78 0.489 NA NA NA
Congenital 0.33 0.319 NA NA NA
Primary angle closure 1.73 0.587 NA NA NA
Penetrating keratoplasty 0.41 0.443 NA NA NA
Early hypertensive phase
Yes 5.15 <0.001 4.88 1.74–11.60 0.002
No
Type of implant
Ahmed S2 0.55 0.141 0.54 0.20–1.46 0.229
Ahmed FP7
IOP: intraocular pressure, OR: odds ratio, CI: confidence interval, and NA: not applicable.
S2: polypropylene; FP7: silicone.
All analyses were performed using generalized estimating equation.
Following AGV implantation, a fibrotic response encap-
sulates the plate of the drainage device, leading to increased
aqueous outflow resistance [19, 20]. Histopathological anal-
ysis from the inner layer of the encapsulated bleb showed
transformation of fibroblasts into myofibroblasts in the col-
lagen fibers. This process is regulated by cytokines, such as
the transforming growth factor-𝛽 (TGF-𝛽) [20, 21], which
mediate the fibrotic process that occurs in patients under-
going glaucoma filtration and drainage implant surgery [22].
Freedman and Iserovich found higher levels of inflammatory
cytokines in the aqueous from patients with encysted blebs
fromMolteno implants [23]. In addition, Trivedi et al. found
a trend toward higher aqueous humor concentrations levels
of TGF-𝛽 in AfricanAmerican subjects, suggesting that racial
differences on inflammatory cytokines levels might explain
differences in failure rates following AGV implant surgeries
[24].
Our study also found that the hypertensive phase was a
risk factor for AGV failure. In our sample, the hypertensive
phase occurred in 33 from the total of 112 eyes (29.4%), among
which 21 failed (63.6%). Previous studies have reported
an incidence of EHP ranging from 56 to 82% following
the implantation of a glaucoma drainage device [10, 25].
The pathophysiological basis underlying the occurrence of
the EHP might be explained by fibroblasts activating an
inflammatory reaction as part of the healing process in the
scar formation, resulting in fibrosis and poor functioning
of the drainage device [26]. In addition, early contact of
aqueous inflammatory mediators with the conjunctiva and
Tenon’s capsule may induce cell death followed by collagen
fiber swelling, fragmentation, and opening of the intercellular
matrix [26]. This wound healing process and scar formation
around the implant create a fibrotic capsule that might make
the aqueous drainage difficult, increasing IOP levels [27].
The material used in glaucoma drainage implants can
also play role in fibrous tissue formation and encapsula-
tion [20]. In fact, Ishida et al. evaluated 132 patients in a
prospective comparative series between silicone (FP7) and
polypropylene (S2) plates [28]. The study found improved
success after implantation of FP7 device compared with
S2 AGV. In addition, a higher incidence of Tenon’s cyst
formation requiring treatment was observed in the S2 group.
Therefore, polypropylene plate material and the occurrence
of a hypertensive phase were considered as risk factors
6 Journal of Ophthalmology
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Figure 2: Percentage of success after Ahmed Glaucoma Valve
implantation in patients with and without the occurrence of the
early hypertensive phase during follow-up, using failure definition of
intraocular pressure greater than 18mmHg and less than 5mmHg.
Univariate analysis showed that early hypertensive phase was a risk
factor for failure (𝑃 < 0.001).
associated with failure [28]. However, in our study there was
no difference in survival rates between the S2 and the FP7
models of the AGV implants (Table 5).
Two recent prospective clinical trials have investigated
the adoption of lower IOP targets during follow-up by ini-
tiating early aqueous suppressants treatment following AGV
implantation [11, 29]. Pakravan et al. evaluated 94 patients
who underwent AGV implantation to study the effects of
early initiation of aqueous suppressant treatment during
postoperative follow-up.These patients were divided into two
different groups, in which the limit for IOPwas 10mmHg and
15mmHg, respectively. They found significantly lower IOP, a
higher success rate, and less frequent hypertensive phases in
eyes that adopted a lower IOP target (10mmHg). The overall
success rate in this group after 1 year of follow-up was 63.2%,
compared to 33.3% in the other group (𝑃 = 0.008) [11]. Law et
al. evaluated 52 eyes undergoing AGV implantation that were
randomized to initiate aqueous suppressant therapy when
postoperative IOP was higher than 10mmHg in one group
or higher than 17mmHg in the other group, during follow-up
[29].They found that humor aqueous suppression in the early
postoperative period while IOPs were still in the low-teens
was able to reduce the incidence of IOP spikes associatedwith
the hypertensive phase without increasing the complications
rate.
We performed a separate analysis within the Caucasian
and African American groups to better investigate the rela-
tionship between EHP and race. Among 14AfricanAmerican
patients without EHP, 9 (64.2%) failed. Among the 8 African
Americans in which EHP occurred, 6 patients (75.0%) failed.
In the Caucasian group, 11 (16.9%) of the 65 patients without
EHP failed and 15 (60.0%) from 25 in which EHP occurred
failed. These findings suggest that, in the African American
group, EHP does not represent a risk factor for failure. In
fact, in the univariate analysis, EHP was not considered a
risk factor in the African American patients (𝑃 = 0.605). On
the other hand, EHP had odds ratio for failure of 7.36 (CI:
2.62–12.62; 𝑃 < 0.001) in the Caucasian group, suggesting
that lowering IOP with early use of aqueous suppressants
might not be as effective in African Americans compared to
Caucasians. Future studies should evaluate prospectively the
impact of racial differences on the early aqueous suppressants
treatment and the onset of EHP.
Our study is limited by its retrospective nature and the
absence of a control arm to compare the results of the AGV
implantation. Although different surgeons were responsible
for the AGV implantation, all surgeries were performed
under direct surgical supervision of experienced attending
glaucoma specialists and followed a standardized technique.
This study was conducted in a public hospital, where the cost
of the AGV implant limits its widespread use. Hence, it is
possible that the sole inclusion of the refractory glaucomas
may have reduced the survival rates of the implant. Also
the indication for new glaucoma procedures was based on
subjective clinical judgment; however, only two patients who
underwent surgical reinterventions had IOPs lower than
18mmHg.
In conclusion, AGV implantation is associated with a rea-
sonable success rate in refractory glaucoma, reaching 47.3%
after 5 years. However, significant differences on survival
rates were observed when adopting a stricter IOP endpoint
(≤15mmHg). African American descendants and patients
who present EHP in the postoperative period are at greater
risk for AGV implantation failure.
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